Objective: To evaluate the efficacy and safety of domestic pemetrexed disodium injection in patients with advanced recurrent lung adenocarcinoma. Methods; Fifty-four patients with advanced recurrent lung adenocarcinoma diagnosed by histology or cytology who had failed to prior chemotherapy were assigned to pemetrexed 500 mg·rn alone every 3 weeks. The efficacy and side effects were assessed after two therapeutic cycles. In accordance with the labeling of pemetrexed disodium injection, patients also received oral dexamethascme, oral folic acid and intramuscular vitamin B12 to reduce toxicity. Results: All patients received more than two cycles of chemotherapy. Among the 54 patients, no one achieved complete response, 7 patients had partial response, 26 patients were stable, and 21 patients had progressed disease. The total response rate was 13.0% (7/54) , and disease control rate was 61. 1% (33/54). The median progression free survival was 3 months. The main adverse events were grade 1 and 2 hematologic toxicities,gastrointestinal toxicities and fatigue. No treatment-related deaths, or treatment interruption due to toxicities were observed. Conclusion; Domestic pemetrexed disodium is effective and well tolerated for monotherapy of patients with advanced recurrent lung adenocarcinoma.%目的:回顾性分析国产培美曲塞二钠单药治疗晚期复发肺腺癌患者的临床疗效及耐受性.方法:54例经组织学或细胞学确诊的晚期肺腺癌患者,均经既往治疗失败,采用国产培美曲塞单药化疗,方案为培美曲塞500 mg·m-2,d1,ivgtt,每3周重复,均按照说明书口服地塞米松、叶酸并肌内注射维生素B12以减轻不良反应,完成2个周期以上化疗后评价疗效和不良反应.结果:54例患者均接受2个周期以上的治疗,全组无完全缓解(CR)病例,部分缓解(PR)7例,疾病稳定(SD) 26例,疾病进展(PD)21例,有效率(CR+ PR)为13.0％ (7/54),疾病控制率(DCR)为61.1％ (33/54),中位无疾病进展时间(PFS)3个月.不良反应主要为Ⅰ/Ⅱ度骨髓抑制、胃肠道反应及乏力,无治疗相关性死亡病例,亦无因不良反应中断治疗的病例.结论:国产培美曲塞单药治疗晚期复发肺腺癌疗效确切,耐受性较好.
展开▼
